We create novel therapeutic antibodies and bio-pharmaceuticals.  Two therapeutic antibodies and one CAR T cell therapy are on clinical trials: Anti-hepatocyte growth factor (HGF)-neutralizing antibody (YYB101 OR NOV1105, phase II clinical trial, NCT04368507); Anti-FAM19A5 antibody (phase I clinical trial, NCT05143463); Anti-CD19 CAR T with a novel anti-CD19 scFv (phase I clinical trial, NCT053338931). An anti-complement C5 antibody was recently approved for phase I clinical trial by FDA.  There are a few more pipelines under preclinical development.

 

We invent novel platform technologies in the field of bispecific antibodies, antibody drug conjugate (ADC) and CAR T cell therapy. Anti-cotinine antibody is now used for a new form of switchable CAR T cell therapy and ADC.

 

We develop algorithms for deciphering B cell repertoire of human and animals using Machine learning and Next Generation Sequencing (NGS) technology. This research provides us valuable information on the immunological process of viral infection, autoimmune disease and carcinogenesis.

 

 

 

 

 

 

 

 

 

Affiliations

Department of Biochemistry and Molecular Biology, Seoul National University College of Medicine

Department of Biomedical Sciences, Seoul National University College of Medicine

Laboratory of Antibody Engineering, Cancer Research Institute, Seoul National University

 

Location

Suites 506-515, Samsung Cancer Research Building

Daehakro 103, Seoul 03080, South Korea (Rep. of Korea)